Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06649071
Enrolling by invitation Observational

Clinical Classification and Imaging Markers in Patients of Obesity

NCT06649071 · tracked via the Priya Life Science China tracker
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase
Observational
Started
2024-10-20
Last updated
2024-10-18

Condition(s) studied

ObesityfMRIClinical Classification

Investigational drug(s) / intervention(s)

Naturalistic observation

Naturalistic observation: Naturalistic observation

Study summary

This is an observational study to explore the etiology and clinical classification in patients with obesity and to achieve personalized treatment.

Eligibility

Sex
ALL
Min age
20 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with BMI≥28kg/m2 * Aged 18-65 years of both sexes, right-handed * At least 6 years of education * Patients agreed and signed the informed consent Exclusion Criteria: * Fewer than 6 years of education * Left-handedness * Dementia * Acute metabolic complications such as diabetic ketoacidosis * Hyperglycaemic hyperosmolar state and hypoglycaemic coma within the previous 3 months; history or presence of neurological or psychiatric disorders; * Presence of hypothyroidism; * History of malignancy, or severe kidney or liver dysfunction.

Primary outcome measure(s)

  • Brain imaging features in patients with obesity by fMRI — From 2024 to 2028
    total brain volume, grey matter volume, white matter volume,cerebrospinal fluid volume, and nuclear bulk volume by MRI-derived normalized measures. All patients underwent odor-induced task fMRI on a 3.0T MR scanner with 222 volumes for task fMRI and 230 volumes for resting-state fMRI.
  • Biomarkers of patients with obesity by blood sample — From 2024 to 2028
    Diagnostic biomarkers, predictive biomarkers, and prognostic biomarker in patients with obesity by blood sample
  • Clinical classification of patients with obesity — From 2024 to 2028
    Based on the exploration of the unique brain imaging and biomarkers in patients with obesity, the clinical classification of obese patients was carried out.
  • Prevention and intervention strategies for obesity based on clinical classification — From 2024 to 2028
    According to the clinical classification of obesity investigated in our previous study, personalized prevention and treatment strategies are designed to effectively slow down or reverse the obesity disease.

Trial sites (1)

FacilityCityRegionStatus
Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing Jiangsu

More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China

Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy Recruiting
Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus Recruiting
CHT105 for the Treatment of Refractory Lupus Nephritis Enrolling by invitation
Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 μg/Kgevery 8 Hours for Three Consecutive Days After Surgery. Recruiting
A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions Recruiting

Other trials for the same condition

Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity Starting soon
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes Recruiting
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity Active, not recruiting
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity Recruiting
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06649071 on ClinicalTrials.gov ↗ ← All trials in China